

WHAT IS CLAIMED:

1. A purified nucleic acid molecule encoding a human KDR protein which consists essentially of the nucleotide sequence

5 ATGGAGAGCAAGGTGCTGCTGGCCGTCGCCCTGTGGCTCTGCGTGGAGACCCGGGCCGCTCTGTGGGT
TTGCCTAGTGTCTCTTGATCTGCCCAGGCTCAGCATACAAAAGACATACTTACAATTAAGGCTAAT
ACAACTCTTCAAATTACTTGCAGGGGACAGAGGGACTTGGACTGGCTTTGGCCCAATAATCAGAGTGGC
AGTGAGCAAAGGGTGGAGGTGACTGAGTGCAGCGATGGCCTCTTCTGTAAGACACTCACAAATCCAAAA
GTGATCGGAAATGACACTGGAGCCTACAAGTGCTTCTACCGGAACTGACTTGGCCTCGGTCAATTTAT
10 GTCTATGTTCAAGATTACAGATCTCCATTTATTGCTTCTGTTAGTGACCAACATGGAGTCGTGTACATT
ACTGAGAACAAAAACAAAACGTGGTGATTCCATGTCTCGGGTCCATTTCAAATCTCAACGTGTCACTT
TGTGCAAGATACCCAGAAAAGAGATTTGTTTCCTGATGGTAACAGAATTTCTGAGACAGCAAGAAGGGC
TTTACTATTCCCAGCTACATGATCAGCTATGCTGGCATGGTCTTCTGTGAAGCAAAAATTAATGATGAA
AGTTACCAGTCTATTATGTACATAGTTGTCGTTGTAGGGTATAGGATTTATGATGTGGTTCTGAGTCCG
15 TCTCATGGAATTGAACTATCTGTTGGAGAAAAGCTTGTCTTAAATTGTACAGCAAGAAGTGAACATAAT
GTGGGGATTGACTTCAACTGGGAATACCCTTCTTCGAAGCATCAGCATAAGAACTTGTAAACCGAGAC
CTAAAAACCCAGTCTGGGAGTGAGATGAAGAAATTTTTGAGCACCTTAAGTATAGATGGTGTAACCCGG
AGTGACCAAGGATTGTACACCTGTGCAGCATCCAGTGGGCTGATGACCAAGAAGAAGCAGCACATTTGTC
AGGGTCCATGAAAAACCTTTTGTGCTTTTGGAAAGTGGCATGGAATCTCTGGTGGAGCCACGGTGGGG
20 GAGCGTGTGAGAATCCCTGCGAAGTACCTTGGTTACCCACCCCCAGAAATAAAATGGTATAAAAATGGA
ATACCCCTTGAGTCCAATCACACAATTAAAGCGGGGCATGTACTGACGATTATGGAAGTGAGTGAAAGA
GACACAGGAAATTACACTGTATCCTTACCAATCCCATTTCAAAGGAGAAGCAGAGCCATGTGGTCTCT
CTGGTTGTGTATGTCCCACCCAGATTGGTGAGAAATCTCTAATCTCTCCTGTGGATTCTTACCAGTAC
GGCACCACTCAAACGCTGACATGTACGGTCTATGCCATTCTCTCCCCGCATCACATCCACTGGTATTGG
25 CAGTTGGAGGAAGAGTGCGCCAACGAGCCCAGCCAAGCTGTCTCAGTGACAAACCCATACCCTTGTGAA
GAATGGAGAAGTGTGGAGGACTTCCAGGGAGGAAATAAAATTGAAGTTAATAAAAATCAATTTGCTCTA
ATTGAAGGAAAAACAAAACCTGTAAGTACCCTTGTATCCAAGCGCAAATGTGTACAGCTTTGTACAAA
TGTGAAGCGGTCAACAAAGTCGGGAGAGGAGAGAGGGTGATCTCCTTCCACGTGACCAGGGGTCCTGAA
ATTACTTTGCAACCTGACATGCAGCCCACTGAGCAGGAGAGCGTGTCTTTGTGGTGCAGTGCAGACAGA
30 TCTACGTTTGAGAACCTCACATGGTACAAGCTTGGCCACAGCCTCTGCCAATCCATGTGGGAGAGTTG
CCCACACCTGTTTGCAAGAACTTGGATACTCTTTGGAAATTGAATGCCACCATGTTCTCTAATAGCACA
AATGACATTTTGTATCATGGAGCTTAAGAATGCATCCTTGCAGGACCAAGGAGACTATGTCTGCCTTGCT
CAAGACAGGAAGACCAAGAAAAGACATTGCGTGGTCAGGCAGCTCACAGTCTAGAGCGTGTGGCACCC
ACGATCACAGGAAACCTGGAGAATCAGACGACAAGTATTGGGGAAAGCATCGAAGTCTCATGCACGGCA
35 TCTGGGAATCCCCCTCCACAGATCATGTGGTTTAAAGATAATGAGACCCTTGTAGAAGACTCAGGCATT
GTATTGAAGGATGGGAACCGGAACCTCACTATCCGCAGAGTGAGGAAGGAGGACGAAGGCCTCTACACC

5 TGCCAGGCATGCAGTGTCTTGGCTGTGCAAAAGTGGAGGCATTTTTCATAATAGAAGGTGCCCAGGAA
 AAGACGAACTTGGAAATCATTATCTAGTAGGCACGGCGGTGATTGCCATGTTCTTCTGGCTACTTCTT
 GTCATCATCCTACGGACCGTTAAGCGGGCCAATGGAGGGGAAGTGAAGACAGGCTACTTGTCCATCGTC
 ATGGATCCAGATGAACTCCCATTGGATGAACATTGTGAACGACTGCCTTATGATGCCAGCAAATGGGAA
 10 TTCCCCAGAGACCGGCTGAAGCTAGGTAAGCCTCTTGGCCGTGGTGCCTTTGGCCAAGTGATTGAAGCA
 GATGCCTTTTGAATTGACAAGACAGCAACTTGCAGGACAGTAGCAGTCAAAATGTTGAAAGAAGGAGCA
 ACACACAGTGAGCATCGAGCTCTCATGTCTGAACTCAAGATCCTCATTTCATATTGGTCAACCATCTCAAT
 GTGGTCAACCTTCTAGGTGCCTGTACCAAGCCAGGAGGGCCACTCATGGTGATTGTGGAATTCTGCAAA
 TTTGGAAACCTGTCCACTTACCTGAGGAGCAAGAGAAATGAATTTGTCCCTACAAGACCAAAGGGGCA
 15 CGATTCCGTCAAGGGAAAGACTACGTTGGAGCAATCCCTGTGGATCTGAAACGGCGCTTGGACAGCATC
 ACCAGTAGCCAGAGCTCAGCCAGCTCTGGATTTGTGGAGGAGAAGTCCCTCAGTGATGTAGAAGAAGAG
 GAAGCTCCTGAAGATCTGTATAAGGACTTCTTGACCTTGGAGCATCTCATCTGTTACAGCTTCCAAGTG
 GCTAAGGGCATGGAGTTCTTGGCATCGCGAAAGTGTATCCACAGGGACCTGGCGGCACGAAATATCCTC
 TTATCGGAGAAGAACGTGGTTAAATCTGTGACTTTGGCTTGGCCCGGGATATTTATAAAGATCCAGAT
 20 TATGTCAGAAAAGGAGATGCTCGCCTCCCTTTGAAATGGATGGCCCCAGAAACAATTTTGTACAGAGTG
 TACACAATCCAGAGTGACGTCTGGTCTTTTGGTGTCTTGTGCTGTGGGAAATATTTCTCTTAGGTGCTTCT
 CCATATCCTGGGGTAAAGATTGATGAAGAATTTTGTAGGCGATTGAAAGAAGGAACTAGAATGAGGGCC
 CCTGATTATACTACACCAGAAATGTACCAGACCATGCTGGACTGCTGGCACGGGGAGCCCAGTCAGAGA
 CCCACGTTTTTCAGAGTTGGTGAACATTTGGGAAATCTCTTGCAAGCTAATGCTCAGCAGGATGGCAAA
 25 GACTACATTGTTCTTCCGATATCAGAGACTTTGAGCATGGAAGAGGATTCTGGACTCTCTCTGCCTACC
 TCACCTGTTTCTGTATGGAGGAGGAGGAAGTATGTGACCCCAAATTCATTATGACAACACAGCAGGA
 ATCAGTCAGTATCTGCAGAACAGTAAGCGAAAGAGCCGGCCTGTGAGTGTAACAACTTTGAAGATATC
 CCGTTAGAAGAACCAGAAGTAAAGTAATCCAGATGACAACCAGACGGACAGTGATGGTTCTTGCC
 TCAGAAGAGCTGAAAACCTTTGGAAGACAGAACCAAATTATCTCCATCTTTTGGTGAATGGTGGCCAGC
 30 AAAAGCAGGGAGTCTGTGGCATCTGAAGGCTCAAACCAGACAAGCGGCTACCAGTCCGGATATCACTCC
 GATGACACAGACACCACCGTGTACTCCAGTGAGGAAGCAGAACTTTTAAAGCTGATAGAGATTGGAGTG
 CAAACCGGTAGCACAGCCCAGATTCTCCAGCCTGACTCGGGGACCACACTGAGCTCTCCTCCTGTTTAA
 (SEQ ID NO:1), wherein said nucleic acid molecule encodes a human
 KDR protein or biologically active form thereof where at least amino acid
 35 residues selected from the group consisting of Val at position 848, Glu at
 position 498, Ala at position 772, Arg at position 787, Lys at position 835
 and Ser at position 1347 are present in said protein.

2. A purified DNA molecule encoding human KDR
 35 wherein said DNA molecule encodes a protein consisting essentially of
 the amino acid sequence:

MESKVLLAVALWLCVETRAASVGLPSVSLDLPRLSIQKDILTIKANTTLQITCRGQRDLDWLWPNQSG
 SEQRVEVTECDGLFCKTLTI PKVIGNDTGAYKCFYRETDLASVIYVYVQDYRSPFIASVSDQHGVVYI
 TENKNKTVVIPCLGSISNLNVSLCARYPEKRFPDGNRISWDSKKGFTIPSYMISYAGMVCFEAKINDE
 SYQSIMYIVVVVGYRIYDVVLSPSHGIELSVGEKLVLNCTARTELVNVDGIDFNWEYPSSKHQHKLVNRD
 5 LKTQSGSEMKKFLSTLTIDGVTRSDQGLYTCAASSGLMTKKNSTFVRVHEKPFVAFGSGMESLVEATVG
 ERVRIPAKYLGYPPEIKWYKNGIPLSNHTIKAGHVLTIMEVSEKDTGNYTVILTNPISKEKQSHVVS
 LVVVYVPPQIGEKSLISPVDSYQYGTQTTLCTVYAIPPPHHIHWYQLEEECANEPSQAVSVTNPYPC
 EWRSVEDFQGGNKIEVNKNQFALIEGKNKTVSTLVIQAANVSALYKCEAVNKVGRGERVISFHVTRGPE
 ITLQPDMPTEQESVSLWCTADRSTFENLTWYKLGQPPLPIHVGEKLPVCKNLDLWKLNATMFSNST
 10 NDILIMELKNASLQDQGDYVCLAQDRKTKKRHCVVRLTVLERVAPTITGNLENQTTSIGESIEVSCA
 SGNPPPQIMWFKDNETLVEDSGIVLKDGNRNLTI RRVKEDGLYTCQACSVLGCAKVEAFFIIEGAQE
 KTNLEIIILVGTAVIAMFFWLLLVIIILRTVKRANGELKTGYLSIVMDPDELPLDEHGERLPYDASKWE
 FPRDRLKLGKPLGRGAFGQVIEADAFGIDKTATCRTVAVKMLKEGATHSEHRALMSELKILIHGHLN
 VVNLGACTKPGGPLMVIVEFCKFGNLSTYLRSKRNEFVYPYKTKGARFRQKDYVGAIPVDLKRRLDSI
 15 TSSQSSASSGFVEEKSLSDVEEEEAPEDLYKDFLTLEHLICYSFQVAKGMEFLASRKC IHRDLAARNIL
 LSEKNVVKICDFGLARDIYKDPDYVRKGDARLPLKWMAPETIFDRVYTIQSDVWSFGVLLWEIFSLGAS
 PYPGVKIDEEFCRRLKEGTRMRAPDYTTPEMYQTM LDCWHGEPSQRPTFSELVEHLGNLLQANAQQDGK
 DYIVLP ISETLSMEEDSGLSLPTSPVSCMEEEEEVCDPKFHYDNTAGISQYLQNSKRKSRPVSVKTFEDI
 PLEPEVKVIPDDNQTDSGMVLASEELKTLEDRTKLSPSFGGMVPSKSRESVASEGSNQTSGYQSGYHS
 20 DDTDTTVYSSEEAECLKLIEIGVQTGSTAQILQPDSGTTLSSPPV, as set forth in a three-
 letter abbreviation in SEQ ID NO:2 and containing amino acid residues
 selected from the group consisting of Val at position 848, Glu at position
 498, Ala at position 772, Arg at position 787, Lys at position 835 and Ser at
 position 1347.

25

3. An expression vector for the expression of a human KDR protein in a recombinant host cell wherein said expression vector comprises the DNA molecule of claim 1.

30

4. An expression vector of claim 3 which is a eukaryotic expression vector.

5. An expression vector of claim 3 which is a prokaryotic expression vector.

35

6. A host cell which expresses a recombinant human KDR protein wherein said host cell contains the expression vector of claim 3.

5 7. A host cell which expresses a recombinant human KDR protein wherein said host cell contains the expression vector of claim 4.

10 8. A host cell which expresses a recombinant human KDR protein wherein said host cell contains the expression vector of claim 5.

15 9. A host cell of claim 6 wherein said human KDR protein is overexpressed from said expression vector.

10. A host cell of claim 7 wherein said human KDR protein is overexpressed from said expression vector.

20 11. A host cell of claim 8 wherein said human KDR protein is overexpressed from said expression vector.

12. A subcellular membrane fraction obtained from the host cell of claim 9 which contains recombinant human KDR protein.

25 13. A subcellular membrane fraction obtained from the host cell of claim 10 which contains recombinant human KDR protein.

30 14. A subcellular membrane fraction obtained from the host cell of claim 11 which contains recombinant human KDR protein.

15. A purified DNA molecule which consists of the nucleotide sequence:

ATGGAGAGCAAGGTGCTGCTGGCCGTCGCCCTGTGGCTCTGCGTGGAGACCCGGGCCGCTCTGTGGGTT
TGCCTAGTGTCTCTCTTGATCTGCCCAGGCTCAGCATACAAAAAGACATACTTACAATTAAGGCTAATAC
35 AACTCTTCAAATTACTTGCAGGGGACAGAGGGACTTGGACTGGCTTTGGCCCAATAATCAGAGTGGCAGT
GAGCAAAGGGTGGAGGTGACTGAGTGCAGCGATGGCCTCTTCTGTAAGACACTCACAATTCCAAAAGTGA

TCGGAAATGACACTGGAGCCTACAAGTGCTTCTACCGGGAAACTGACTTGGCCTCGGTCAATTTATGTCTA
 TGTTCAGATTACAGATCTCCATTTATTGCTTCTGTAGTGACCAACATGGAGTCGTGTACATTACTGAG
 AACAAAAACAAAACGTGGTGATTCCATGTCTCGGGTCCATTTCAAATCTCAACGTGTCACTTTGTGCAA
 GATACCCAGAAAAGAGATTTGTTCTGTATGGTAACAGAATTTCTCTGGGACAGCAAGAAGGGCTTTACTAT
 5 TCCCAGCTACATGATCAGCTATGCTGGCATGGTCTTCTGTGAAGCAAAAATTAATGATGAAAGTTACCAG
 TCTATTATGTACATAGTTGTCTGTAGGGTATAGGATTTATGATGTGGTTCTGAGTCCGTCTCATGGAA
 TTGAACTATCTGTTGGAGAAAAGCTTGTCTTAAATTTGTACAGCAAGAACTGAACTAAATGTGGGGATTGA
 CTTCAACTGGGAATACCCCTTCTTCGAAGCATCAGCATAAGAACTTGTAAACCGAGACCTAAAAACCCAG
 TCTGGGAGTGAGATGAAGAAATTTTTGAGCACCTTAACTATAGATGGTGTAAACCCGGAGTGACCAAGGAT
 10 TGTACACCTGTGCAGCATCCAGTGGGCTGATGACCAAGAAGAACAGCACATTTGTGAGGGTCCATGAAAA
 ACCTTTTGTGCTTTTGGAGTGGCATGGAATCTCTGGTGGAAGCCACGGTGGGGGAGCGTGTGAGAATC
 CCTGCGAAGTACCTTGGTTACCCACCCCCAGAAATAAAATGGTATAAAAAATGGAATACCCCTTGAGTCCA
 ATCACACAATTAAAGCGGGGCATGTACTGACGATTATGGAAGTGAGTGAAAGAGACACAGGAAATTACAC
 TGTATCCTTACCAATCCCATTTCAAAGGAGAAGCAGAGCCATGTGGTCTCTCTGGTTGTGTATGTCCCA
 15 CCCCAGATTGGTGAGAAATCTCTAATCTCTCTCTGTGGATTTCCTACCAGTACGGCACCACTCAAACGCTGA
 CATGTACGGTCTATGCCATTCTCTCCCCGCATCACATCCACTGGTATTGGCAGTTGGAGGAAGAGTGCGC
 CAACGAGCCCAGCCAAGCTGTCTCAGTGACAAACCCATACCCCTTGTGAAGAATGGAGAAGTGTGGAGGAC
 TTCCAGGGAGGAAATAAAATTGAAGTTAATAAAAAATCAATTTGCTCTAATTGAAGGAAAAAACAAAACCTG
 TAAGTACCCCTTGTATCCAAGCGGCAAATGTGTCAGCTTTGTACAAATGTGAAGCGGTCAACAAAGTCGG
 20 GAGAGGAGAGAGGGTGATCTCCTTCCACGTGACCAGGGTCTTGAATTACTTTGCAACCTGCATGCGAG
 CCCACTGAGCAGGAGAGCGTGTCTTTGTGGTGCACTGCAGACAGATCTACGTTTGAGAACCTCACATGGT
 ACAAGCTTGGCCACAGCCTCTGCCAATCCATGTGGGAGAGTTGCCACACCTGTTTGCAAGAACTTGGA
 TACTCTTTGGAAATTGAATGCCACCATGTTCTCTAATAGCACAAATGACATTTTGATCATGGAGCTTAAG
 AATGCATCCTTGCAGGACCAAGGAGACTATGTCTGCCTTGCTCAAGACAGGAAGACCAAGAAAAGACATT
 25 GCGTGGTCAGGCAGCTCACAGTCTAGAGCGTGTGGCACCCACGATCACAGGAAACCTGGAGAATCAGAC
 GACAAGTATTGGGGAAAGCATCGAAGTCTCATGCACGGCATCTGGGAATCCCCCTCCACAGATCATGTGG
 TTTAAAGATAATGAGACCCTTGTAAGAAGCTCAGGCATTGTATTGAAGGATGGGAACCGGAACCTCACTA
 TCCGCAGAGTGAGGAAGGAGGACGAAGGCCCTTACACCTGCCAGGCATGCAGTGTCTTGGCTGTGCAA
 AGTGGAGGCATTTTTTCATAATAGAAGGTGCCCAGGAAAAGACGAACCTTGGAATCATTATTCTAGTAGGC
 30 ACGGCGGTGATTGCCATGTTCTTCTGGCTACTTCTTGTTCATCATCCTACGGACCGTTAAGCGGGCCAATG
 GAGGGGAACCTGAAGACAGGCTACTTGTCCATCGTCATGGATCCAGATGAACTCCCATTGGATGAACATTG
 TGAACGACTGCCTTATGATGCCAGCAAAATGGGAATTCCCCAGAGACCGGCTGAAGCTAGGTAAGCCTCTT
 GGCCGTGGTGCCTTTGGCCAAGTGATTGAAGCAGATGCCTTTTGAATTGACAAGACAGCAACTTGCAGGA
 CAGTAGCAGTCAAAATGTTGAAAGAAGGAGCAACACACAGTGAGCATCGAGCTCTCATGTCTGAACTCAA
 35 GATCCTCATTCATATTGGTCACCATCTCAATGTGGTCAACCTTCTAGGTGCCTGTACCAAGCCAGGAGGG
 CCACTCATGGTGATTGTGGAATTCTGCAAAATTTGGAAACCTGTCCACTTACCTGAGGAGCAAGAGAAATG

AATTTGTCCCCTACAAGACCAAAGGGGCACGATTCCGTCAAGGGAAAGACTACGTTGGAGCAATCCCTGT
 GGATCTGAAACGGCGCTTGGACAGCATCACCAGTAGCCAGAGCTCAGCCAGCTCTGGATTTGTGGAGGAG
 AAGTCCCTCAGTGATGTAGAAGAAGAGGAAGCTCCTGAAGATCTGTATAAGGACTTCTTGACCTTGGAGC
 ATCTCATCTGTTACAGCTTCCAAGTGGCTAAGGGCATGGAGTTCTTGGCATCGCGAAAGTGTATCCACAG
 5 GGACCTGGCGGCACGAAATATCCTCTTATCGGAGAAGAACGTGGTTAAAATCTGTGACTTTGGCTTGGCC
 CGGGATATTTATAAAGATCCAGATTATGTCAGAAAAGGAGATGCTCGCCTCCCTTTGAAATGGATGGCCC
 CAGAAACAATTTTTGACAGAGTGACACAATCCAGAGTGACGTCTGGTCTTTTGGTGTTTTGTCTGTGGGA
 AATATTTTCCTTAGGTGCTTCTCCATATCCTGGGGTAAAGATTGATGAAGAATTTTGTAGGCGATTGAAA
 GAAGGAAC TAGAATGAGGGCCCTGATTATACTACACCAGAAATGTACCAGACCATGCTGGACTGCTGGC
 10 ACGGGGAGCCCAGTCAGAGACCCACGTTTTTCAGAGTTGGTGGAACATTTGGGAAATCTCTTGCAAGCTAA
 TGCTCAGCAGGATGGCAAAGACTACATTGTTCTTCCGATATCAGAGACTTTGAGCATGGAAGAGGATTCT
 GGACTCTCTCTGCCTACCTCACCTGTTTCTGTATGGAGGAGGAGGAAGTATGTGACCCCAAATTCCATT
 ATGACAACACAGCAGGAATCAGTCAGTATCTGCAGAACAGTAAGCGAAAGAGCCGGCCTGTGAGTGATAA
 AACATTTGAAGATATCCCGTTAGAAGAACCAGAAGTAAAAGTAATCCCAGATGACAACCAGACGGACAGT
 15 GGTATGGTTCCTTGCCTCAGAAGAGCTGAAAACCTTTGGAAGACAGAACCAAATTATCTCCATCTTTTGGTG
 GAATGGTGCCCAGCAAAGCAGGGAGTCTGTGGCATCTGAAGGCTCAAACCAGACAAGCGGCTACCAGTC
 CGGATATCACTCCGATGACACAGACACCACCGTGTACTCCAGTGAGGAAGCAGAACTTTTAAAGCTGATA
 GAGATTGGAGTGCAAACCGGTAGCACAGCCCAGATTCTCCAGCCTGACTCGGGGACCACACTGAGCTCTC
 CTCCTGTTTAA, disclosed as SEQ ID NO:1.

20

16. A purified human KDR protein which consists of the amino acid sequence

MESKVLVALVALWLCVETRAASVGLPSVSLDLPRLSIQKDILTIKANTTLQITCRGQRDLWLWPNQSG
 SEQRVEVTECDGLFCKTLTI PKVIGNDTGAYKCFYRETDLASVIYVYVQDYRSPFIASVSDQHGVYI
 25 TENKNKTVVIPCLGSISNLNVSLCARYPEKRFVPDGNRISWDSKKGFTIPSYMISYAGMVFEAKINDE
 SYQSIMYIVVVVGYRIYDVVLSPSHGIELSVGEKLVLNCTARTELVNGIDFNWEYPSSKHQHKLVNRD
 LKTQSGSEMKKFLSTLTIDGVTRSDQGLYTCAASSGLMTKKNSTFVRVHEKPFVAFSGMESLVEATVG
 ERVRIPAKYLGYPPEIKWYKNGI PLESNHTIKAGHVLTIMEVSEKDTGNYTVILTNPISKEKQSHVVS
 LVVYVPPQIGEKSLISPVD SYQYGTQTCTVYAIPPPHHIHWWQLEEECANEPSQAVSVTNPYPCPE
 30 EWRSVEDFQGGNKIEVNKNQFALIEGKNKTVSTLVIQAANVSALYKCEAVNKVGRGERVISFHVTRGPE
 ITLQPDMPTEQESVSLWCTADRSTFENLTWYKLGPOPLPIHVGE LPTPVCKNLDTLWKL NATMFSNST
 NDILIMELKNASLQDQGDYVCLAQDRKTKKRHCVRQLTVLERVAPTITGNLENQTTSIGESIEVSC TA
 SGNPPPQIMWFKDNETLVEDSGIVLKDGNRNLTI RRVKEDGLYTCQACSVLGCAKVEAFFIIEGAQE
 KTNLEIIILVGTAVIAMFFWLLLVIILRTVKRANGGELKTGYLSIVMDPDELPLDEH CERLPYDASKWE
 35 FPRDLRLKLGKPLGRGAFGQVIEADAFGIDKTATCRTVAVKMLKEGATHSEHRALMSELKILIHIGHHLN
 VVNLGACTKPGGPLMVIVEFCKFGNLSTYLRSKRNEFVYPYKTKGARFRQGDYVGAI PVDLKRRLDSI

TSSQSSASSGFVEEKSLSDVEEEEAPEDLYKDFLTLEHLICYSFQVAKGMEFLASRKC IHRDLAARNIL
 LSEKNVVKICDFGLARDIYKDPDYVRKGDARLPLKWMAPETIFDRVYTIQSDVWSFGVLLWEIFSLGAS
 PYPGVKIDEEFCRRLKEGTRMRAPDYTTPEMYQTMLDCWHGEPSQRPTFSELVEHLGNLLQANAQQDGK
 DYIVLPISETLSMEEDSGLSLPTSPVSCMEEEEVCDPKFHYDNTAGISQYLQNSKRKSRPVSVKTFEDI
 5 PLEEPEVKVIPDDNQTDSGMVLASEELKTLEDRTKLSPSFGGMVPSKSRESVASEGSNQTSGYQSGYHS
 DDTDTTVYSSEEAEELLKLEIGVQTGSTAQILQPDSGTTLSPPV, as set forth in three
 letter abbreviation in SEQ ID NO:2 and containing amino acid residues
 selected from the group consisting of Val at position 848, Glu at position
 498, Ala at position 772, Arg at position 787, Lys at position 835 and Ser at
 10 position 1347.

17. The purified human KDR protein of claim 16 as set forth in SEQ ID NO:2.

18. A process for the expression of a human KDR protein in a recombinant host cell, comprising:

(a) transfecting the expression vector of claim 3 into a suitable host cell; and,

(b) culturing the host cells of step (a) under conditions which allow expression of the human KDR protein from the expression vector.

19. An expression vector for the expression of a human KDR protein in a recombinant host cell wherein said expression vector comprises the DNA molecule of claim 15.

20. A purified nucleic acid molecule encoding an intracellular portion of a human KDR protein which comprises from about amino acid 790 to about amino acid 1356 as set forth in SEQ ID NO: 2, wherein position 848 is a valine residue.

21. A purified nucleic acid molecule of claim 20 encoding an intracellular portion of a human KDR protein which comprises from about amino acid 790 to about amino acid 1356 as set forth in SEQ ID NO:

2, wherein position 772 is an alanine residue, position 787 is an arginine residue, position 835 is a lysine residue, position 848 is a valine residue and position 1347 is a serine residue.

5 22. An expression vector for the expression of a human KDR protein in a recombinant host cell wherein said expression vector comprises the DNA molecule of claim 20.

10 23. An expression vector for the expression of a human KDR protein in a recombinant host cell wherein said expression vector comprises the DNA molecule of claim 21.

15 24. A purified protein fragment which is an intracellular portion of a human KDR protein, comprising from about amino acid 790 to about amino acid 1356 as set forth in SEQ ID NO: 2, wherein position 848 is a valine residue.

20 25. A purified protein fragment of claim 24 which comprises from about amino acid 790 to about amino acid 1356 as set forth in SEQ ID NO: 2, wherein position 772 is an alanine residue, position 787 is an arginine residue, position 835 is a lysine residue, position 848 is a valine residue and position 1347 is a serine residue.

25 26. A purified nucleic acid molecule encoding an soluble KDR fusion protein which comprises from about amino acid 790 to about amino acid 1356 of human KDR as set forth in SEQ ID NO: 2, wherein position 848 is a valine residue.

30 27. A purified nucleic acid molecule of claim 26 wherein said KDR fusion protein comprises from about amino acid 790 to about amino acid 1356 as set forth in SEQ ID NO: 2, position 772 being an alanine residue, position 787 being an arginine residue, position 835 being a lysine residue, position 848 being a valine residue and position 1347 being a serine residue.

35

28. A purified nucleic acid molecule of claim 27 which encodes GST-KDR.

5 29. An expression vector for the expression of a human KDR protein in a recombinant host cell wherein said expression vector comprises the DNA molecule of claim 26.

10 30. An expression vector for the expression of a human KDR protein in a recombinant host cell wherein said expression vector comprises the DNA molecule of claim 27.

15 31. An expression vector for the expression of a human KDR protein in a recombinant host cell wherein said expression vector comprises the DNA molecule of claim 28.

20 32. A purified KDR fusion protein which is characterized by an intracellular portion of a human KDR protein, comprising from about amino acid 790 to about amino acid 1356 as set forth in SEQ ID NO: 2, wherein position 848 is a valine residue.

25 33. A purified KDR fusion protein of claim 32 which comprises from about amino acid 790 to about amino acid 1356 as set forth in SEQ ID NO: 2, wherein position 772 is an alanine residue, position 787 is an arginine residue, position 835 is a lysine residue, position 848 is a valine residue and position 1347 is a serine residue.

34. The purified KDR fusion protein of claim 33 which is GST-KDR.

30 35. A purified nucleic acid molecule encoding an extracellular portion of a human KDR protein which comprises from about amino acid 1 to about amino acid 644 as set forth in SEQ ID NO:2, wherein position 498 is a glutamic acid residue.

36. An expression vector for the expression of a human KDR protein in a recombinant host cell wherein said expression vector comprises the DNA molecule of claim 36.

5 37. A purified protein fragment which is an extracellular portion of a human KDR protein, comprising from about amino acid 1 to about amino acid 790 as set forth in SEQ ID NO: 2, wherein position 498 is a glutamic acid residue, position 772 is an alanine residue and position 787 is an arginine residue.

10 38. An isolated nucleic acid molecule of claim 20 wherein a termination codon is inserted such that the KDR open reading frame terminates at about Tyr 1175.

15 39. An isolated nucleic acid of claim 38 which is contained within a DNA vector, pBlueBacHis2B.

40. The DNA vector of claim 39 which is pBBH-KDR-1.

20 41. A method of selecting a compound which antagonizes human KDR which comprises a biological assay wherein a test compound is added in combination with a KDR protein or protein fragment and a substrate, said substrate being involved in a measurable interaction at a domain of interest within wild-type KDR such that
25 compound antagonist interacts with said KDR protein, resulting in a measurable decrease in KDR:substrate activity.

42. A method of claim 41 wherein said KDR protein is GST/KDR-1.

30 43. A method of claim 42 wherein said substrate is pEY.

35 44. A method of selecting a compound which is an agonist of human KDR which comprises a biological assay wherein a test compound is added in combination with a KDR protein or protein fragment and a substrate, said substrate being involved in a measurable

interaction at a domain of interest within wild-type KDR such that a compound antagonist interacts with said KDR protein, resulting in a measurable increase in KDR:substrate activity.

5

45. A method of claim 44 wherein said KDR protein is GST/KDR-1.

46. A method of claim 45 wherein said substrate is pEY.

10

FOOTNOTES